The FDA removed more menopause hormone warnings — here is what changed, what did not, and why the process itself is being questioned

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Watchdog coverage exists for moments exactly like this one: a consequential label change that many clinicians welcome, announced with more confidence than documentation. Both things can be true — the old boxed warnings were written for a different era's data and overstated risk for many women under 60 or within ten years of menopause, as the FDA argues — and the public deserves to see the evidence worked in the open, as its critics argue. This page separates the three.

What exactly did the FDA change on October 30?

Per the HHS announcement, the FDA approved removal of the same outdated risk statements — regarding cardiovascular disease, breast cancer and probable dementia — from the boxed-warning sections of three additional MHT products, all estradiol transdermal patches from two applicants (the products and applicants were not named in the announcement). In February 2026 the agency had approved similar changes for six MHT products. HHS says the changes follow a thorough re-examination of the scientific literature on benefit-risk, that FDA began engaging companies on revisions in November 2025, and that 29 companies have submitted proposed changes to date. Separately, the agency is expediting manufacturing changes to increase MHT capacity and availability, and exploring whether some vaginal estrogen products could be switched to over-the-counter status — a change that would require evidence consumers can use them safely and effectively without physician supervision, and which has not been approved. HHS framed the action under the October 19, 2026 executive order 'Advancing Women's Health to Improve Outcomes in All Phases of Life.'

Where do mitochondria fit — and where do they not?

The established biology: estrogen is not only a reproductive hormone but a metabolic one. Estrogen receptors, including receptor pools located in mitochondria, help regulate respiratory-chain gene expression, ATP production and antioxidant defenses, and the menopausal decline in estrogen coincides with measurable shifts in energy metabolism, body composition and vascular function. That biology is part of why hormone-therapy research increasingly measures metabolic endpoints. The boundary matters as much as the biology: this labeling action was a benefit-risk reassessment of menopausal symptom treatment based on the cardiovascular, cancer and dementia literature — it contained no mitochondrial endpoints, and it does not make hormone therapy a 'mitochondrial treatment,' a longevity intervention, or appropriate for women outside the populations the benefit-risk assessment covers. Readers will see the label change marketed in mitochondrial and longevity language within weeks; that language is not in the label.

What are critics actually objecting to?

Not necessarily to the destination — many specialists have argued for years that class-wide boxed warnings, derived largely from older trials in older women, misstate the risk for younger, recently menopausal women. The objection reported in coverage of the October 30 action is to the route: no formal advisory committee meeting was convened for these changes, and critics including Yale health-services researcher Reshma Ramachandran, quoted by The Guardian, raised concerns about transparency and the limited public detail on the underlying evidence presented with the announcement. Process is not pedantry in drug regulation — advisory review is where assumptions get challenged in public, and skipping it places the full weight of trust on the agency's internal reassessment. The practical guidance for readers is unchanged by either side's framing: hormone therapy remains an individual decision with a clinician who knows your history, the endometrial-cancer boxed warning for systemic estrogen-alone products remains, and 'the FDA removed a warning' is not the same sentence as 'the FDA found this risk-free.'

Where the evidence stands

• Established: Estrogen signaling influences mitochondrial function — mitochondrial estrogen receptors regulate respiratory-chain activity and antioxidant defenses — and menopause involves real metabolic change; boxed warnings on MHT products historically derived largely from trials in older populations, and the endometrial-cancer warning for systemic estrogen-alone products remains in place.
• Preliminary: The FDA's reassessment, per HHS (Oct 30, 2026), concluded the cardiovascular, breast-cancer and probable-dementia statements were outdated for the benefit-risk profile of the products concerned, extending changes made for six products in February 2026 — a regulatory judgment that critics argue was reached without advisory-committee review or detailed public evidence presentation.
• Absent: Any mitochondrial endpoint in the labeling decision, any approval of hormone therapy to improve mitochondrial function or longevity, and any approval (so far) of over-the-counter vaginal estrogen.